In response to the nationwide shortage of ranitidine and other H2 antagonists, BOPA have produced a guideline on the use of H2 antagonists for the prevention and management of hypersensitivity to assist with clinical decision making.
Click here to view the guideline.
We are also planning a national service evaluation to monitor the impact of the shortage – details to follow soon. Watch this space!
You are invited to take part in a research study called SWEET-PLUS (NIHR Research for Patient Benefit: 207952), run by Newcastle and Oxford Brookes Universities. SWEET-PLUS aims to understand experiences…
Dear BOPA members Due to unforeseen circumstances tomorrow’s webinar AI Implementation: Taking a chemotherapy risk prediction AI model from research into industry and practice (10th March 2026) had to be cancelled. Will…
Dear BOPA Members and Digital SACT Verification Passport Users This is a reminder to all super-managers, managers and assessors of the BOPA SACT Passport to: – Ensure all staff within your Passport…
Abstract Submission for the 29th Annual BOPA Conference 2026 opens on 30th March 2026 Delegates are invited to present results of their clinical and technical work as a…
The 29th BOPA Annual Conference in 2026 will be held at the ICC London Olympia on 2-4 October 2026.
Check out the latest information here: Latest Conference 2026 – BOPA
Everything you need to know
